![Teva Canada Announces Availability of Aermony RespiClick™, an Innovative New Device for the Treatment of Bronchial Asthma | BioSpace Teva Canada Announces Availability of Aermony RespiClick™, an Innovative New Device for the Treatment of Bronchial Asthma | BioSpace](https://mms.businesswire.com/media/20201005005212/en/826961/4/AermonyRespiClick_ENG.jpg)
Teva Canada Announces Availability of Aermony RespiClick™, an Innovative New Device for the Treatment of Bronchial Asthma | BioSpace
![Phil and Teva Pharmaceuticals Launch New Program to Improve Access to the Digihaler® Family of Inhalers to Support Asthma Management | Business Wire Phil and Teva Pharmaceuticals Launch New Program to Improve Access to the Digihaler® Family of Inhalers to Support Asthma Management | Business Wire](https://mms.businesswire.com/media/20230606005187/en/1602634/22/Logo.jpg)
Phil and Teva Pharmaceuticals Launch New Program to Improve Access to the Digihaler® Family of Inhalers to Support Asthma Management | Business Wire
![Teva Introduces Inhalation Powder and Generic Version in U.S. for Asthma Treatment - Drug Discovery and Development Teva Introduces Inhalation Powder and Generic Version in U.S. for Asthma Treatment - Drug Discovery and Development](https://drugdiscoverytrends.com/wp-content/uploads/2019/10/Inhaler.png)
Teva Introduces Inhalation Powder and Generic Version in U.S. for Asthma Treatment - Drug Discovery and Development
![Teva Pharmaceuticals Announces Launch of Daily Maintenance Asthma Medication | Asthma and Allergy Foundation of America Teva Pharmaceuticals Announces Launch of Daily Maintenance Asthma Medication | Asthma and Allergy Foundation of America](https://community.aafa.org/fileSendAction/fcType/0/fcOid/510642830861510679/filePointer/510642830861510701/fodoid/510642830861510696/imageType/LARGE/inlineImage/true/Teva-announced-launch-of-new-daily-asthma-medicine.png)
Teva Pharmaceuticals Announces Launch of Daily Maintenance Asthma Medication | Asthma and Allergy Foundation of America
Teva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and Asthma
![Teva Launches Two Digital Inhalers in the U.S., AirDuo® Digihaler® (fluticasone propionate and salmeterol) Inhalation Powder and ArmonAir® Digihaler® (fluticasone propionate) Inhalation Powder | Business Wire Teva Launches Two Digital Inhalers in the U.S., AirDuo® Digihaler® (fluticasone propionate and salmeterol) Inhalation Powder and ArmonAir® Digihaler® (fluticasone propionate) Inhalation Powder | Business Wire](https://mms.businesswire.com/media/20200921005170/en/820285/4/TEVA_DH-ArmonAir_Inhaler_TiltR_W.jpg)